中新网9月18日电 据国家发展和改革委员会网站消息，国家发展改革委决定从10月8日起调整部分抗肿瘤、免疫和血液系统类等药品的最高零售限价，共涉及95个品种、200多个代表剂型规格，平均降价幅度为17%。

Beijing on September 18, according to the national development and reform commission website news,The national development and reform commission decided to from October 8 up to regulate some antitumor/The immune and blood system drugs such as the highest retail price,Inoled a total of 95 varieties/More than 200 delegates dosage form specification,The average price cut of 17%.

　　国家发展改革委有关负责人介绍，这次价格调整方案是在开展成本价格调查、专家评审和听取有关方面意见的基础上形成的。抗肿瘤、免疫和血液系统类等药品费用高，对患者影响大，降低价格可以有效减轻患者负担。

The national development and reform commission relevant controller introduces,The price adjustment scheme is in developing cost price survey/Expert review and listen to the opinions of the formed on the basis of.antitumor/The immune and blood system such as the high cost of drugs,For patients with big influence,Lower the price can effectively reduce the burden of patients.

　　国家发展改革委有关负责人指出，这次价格调整对日费用高的药品加大了降价力度、对日费用低的药品不降价，鼓励价格相对低廉药品的生产供应；对部分临床供应紧张的血液制品适当提高了价格；对专利等创新型药品适当控制降价幅度，利用价格杠杆促进药品的研发创新；对原单独定价药品，进一步缩小了与统一定价药品之间的价差，以促进市场公平竞争。

The national development and reform commission officials pointed out,The price adjustment, to the high cost of drugs increase the price cut strength/To low cost, the drug is not depreciate,Encourage price are relatively cheap drugs production supply;For some clinical supplies blood products appropriately raise the price;Such as patent innovative drug properly control the price range,Use the price lever to promote the pharmaceutical research and development innovation;The original single drug pricing,Further narrowed and unified pricing between drug price,In order to promote fair competition in the market.